| Document |
Document Title |
|
WO/2006/066436A1 |
A process for the cyclopropanation of a substituted alkene, comprising the reaction of the alkene with a carbenoide, generated from dibromomethane and a tri-(C2 - C8)-alkyl aluminium compound, in the presence of a catalytic amount of a m...
|
|
WO/2006/066746A1 |
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1, R2, R3 and R4 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of...
|
|
WO/2006/064299A1 |
The present invention describes a process for preparing Clarithromycin having 6,11-0dimethyl erythromycin-A in less than 1 % amount. The methylation process in the present invention provides Clarithromycin having free of Claritromycin-...
|
|
WO/2006/044379A2 |
The present invention relates to compounds capable of acting as androgen receptor, antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agen...
|
|
WO/2006/041636A2 |
This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound o...
|
|
WO/2006/036131A1 |
The present invention relates to a novel compound represented as by formula (I). The present invention also provides a novel strain named as Alternaria alternata var. monosporus, which can produce the compound of formula (I). The inventi...
|
|
WO/2006/032683A1 |
The invention relates to a novel antibiotic from the macrolactin group and a microbial method for production of macrolactins and a novel isolated Bacillus subtilis, of application as the producing strain for the known Macrolactin A and t...
|
|
WO/2006/034478A2 |
The present invention provides compounds having formula (I): (I) wherein n, R1-R5, Ra-Rb, Q, Y1 and Y2 are as defined herein; and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use ther...
|
|
WO/2006/010459A1 |
Process for the preparation of olopatadine (I), which comprises reacting a compound of formula (V) in the presence of a palladium catalyst to provide a compound of formula (VI), wherein the acid protecting group is removed to provide the...
|
|
WO/2006/012135A1 |
Quaternary salt compounds of Formula (I) or pharmaceutically acceptable forms thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a sub...
|
|
WO/2006/009093A1 |
Disclosed is a medicament for preventing and/or treating sleep disorders which contains a dibenzo[b,e]oxepin derivative represented by the formula (I) below or a pharmacologically acceptable salt thereof as an active constituent. (In the...
|
|
WO/2006/002721A1 |
The present invention relates to new 5-alkenone-3,3-dimethyl-benzoxepines derivatives of formula (I), their use for the preparation of pentadienoic derivatives and their process of preparation.
|
|
WO2005103041A9 |
The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention ...
|
|
WO/2005/117588A2 |
Dictyostatin and its analogs show great promise as new anticancer agents. The present invention provides dictyostatin analogs, synthetic intermediates for the synthesis of dictyostatin analogs, and synthetic methods for the synthesis of ...
|
|
WO/2005/111012A1 |
The present invention relates to new 3,3-dimethyl-5-cyano-benzoxepines derivatives, their use for the preparation of 5-formyl-benzoxepine derivatives and their process of preparation.
|
|
WO/2005/105773A1 |
Among the compounds represented by the general formula (1) [wherein n is an integer of 7 to 13], 11-methyl-13-tridecanolide (n=8), 12-methyl-14-tetradeca- nolide (n=9), and 13-methyl-15-pentadecanolide (n=10) are novel compounds which ha...
|
|
WO/2005/101950A1 |
The invention relates to a new synthetic process for the production of key intermediates useful in the synthesis of epothilones or epothilone derivatives, to certain compounds used to produce these key intermediates and to a process to p...
|
|
WO/2005/102313A1 |
A preventive and/or therapeutic agent for chronic sinusitis which contains as an active ingredient a dibenzo[b,e]oxepine derivative represented by the following formula (I) (wherein R1, R2, and R3 are the same or different and each repre...
|
|
WO/2005/102977A1 |
The present invention relates to the compounds of general formula (I): wherein R, R1, R2 are as defined in claim 1. Compounds of formula (I) are particularly useful for preparing 3,3-dimethyl-5-formyl-2,3-dihydrobenzoxepines derivatives.
|
|
WO/2005/100329A1 |
New protecting reagents are provided that allow for the selective placement of a new protecting group onto a reactive site of a multifunctional compound. The reagents are 2, 3, and 4-trialkylsilylxylyl, triarylsilylxylyl or a combination...
|
|
WO/2005/097104A1 |
A solid pharmaceutical preparation which contains either a dibenz[b,e]oxepine derivative represented by the following formula (I) [wherein A represents a single bond, -CH=CH-, or (CH2)n- (wherein n is an integer of 1-3); and R1 and R2 ar...
|
|
WO/2005/092876A1 |
The present invention provides new strategies for the synthesis of compounds of the rocaglamide family and related natural products. In particular, the new biomimetic synthetic approach involves photochemical generation of an oxidopyryli...
|
|
WO/2005/092323A1 |
It is intended to provide a compound which is useful in preventing and treating arteriosclerosis-related diseases because of binding to a receptor as a ligand specific to human liver X receptor &agr (LXR&agr ), i.e., a nuclear receptor, ...
|
|
WO/2005/090337A1 |
A compound of the formula (I) (I) wherein the variables X1 to X6, Ra, Rb, R1 to R7 including R3', E, p, j, y, z, A, B and C are as described or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures t...
|
|
WO/2005/079785A1 |
Preventive or therapeutic agents for hyperuricemia and/or gout which little produce adverse effect, containing as the active ingredient substances having both dibenzo[b,f]thiepin or dibenzo[b,f]oxepin skeletons and antioxidant substituen...
|
|
WO/2005/073223A1 |
A method of stabilizing a macrolide compound and a process for efficiently producing the compound. The method, which is for stabilizing a 12-membered cyclic macrolide compound, e.g., that represented by the formula (I), comprises causing...
|
|
WO/2005/070405A1 |
Methods of using certain &agr -aminoamide derivatives to treat lower urinary tract disorders. The therapeutic agents of the invention are able to reduce or even stop the lower urinary tract disorders substantially without side effects.
|
|
WO/2005/068451A2 |
A method for the synthesis of dictyostatin or a derivative thereof having Formula (I) is provided.
|
|
WO/2005/067919A1 |
The present invention discloses compounds of formulae I, II, III or IV or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I), (II), (III), (IV), which exhibit antibacterial properties. The present invention further relat...
|
|
WO/2005/061481A1 |
The present invention relates to compounds having the structure (and pharmaceutically acceptable derivatives thereof) (I) wherein R,,-R4, Z, X, A-B, D-E, G-J, and K-L are as defined herein, the synthesis thereof and the use of these comp...
|
|
WO/2005/053676A1 |
The use of a pentadienoic acid derivative of formula (I) for the preparation of a medicament for the prevention or treatment of hyperuricemia and/or one or several associated disorders or diseases, and/or for reducing the serum uric acid...
|
|
WO/2005/051895A1 |
Disclosed are &dgr -amino-&gammad -hydroxy-&ohgr -aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and ...
|
|
WO/2005/030749A1 |
Novel calcilytic compounds and methods of using them are provided.
|
|
WO/2005/023772A1 |
The invention relates to malonamide derivatives of formula (I), wherein: R1 is one of the following groups (Formulae a), b), c), d)); R2 is lower alkyl, lower alkinyl, -(CH2)n-O-lower alkyl, -(CH2)n-S-lower alkyl, -(CH2)n-CN, -(CR'R')n-C...
|
|
WO/2005/023792A2 |
The present invention provides compositions comprising compounds having formula (I): and additionally provides methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorder...
|
|
WO/2005/023831A1 |
The invention relates to detection of cholesterol ozonation products that are generated by atherosclerotic plaque material, and to methods of detecting vascular conditions that relate to the accumulation and oxidation of cholesterol.
|
|
WO/2005/023830A2 |
As illustrated herein, cholesterol is oxidized when it is present in atherosclerotic plaques. This reaction generates cytotoxic cholesterol oxidation or ozonation products. The present application is directed to the products of cholester...
|
|
WO2004087673B1 |
The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metas...
|
|
WO/2005/018674A1 |
A drug containing, as the active ingredient, a compound having an Hsp90 inhibitory effect or a pharmacologically acceptable salt thereof is used as a remedy for diseases associated with the translocation of immunoglobulin gene. In the di...
|
|
WO/2005/019181A1 |
The invention relates to compositions and methods useful for inhibiting cell migration. These compositions and methods can be used to inhibit metastasis of tumor cells in mammals. The compositions are characterized by comprising a coumpo...
|
|
WO/2005/014517A2 |
The present invention pertains to compounds of formula (I) wherein X is O, NH, N(C1-4)alkyl, CO or CHOH, Y is CH or N, A and B are each hydrogen or together form a second bond between the carbon atoms to which they are attached, R1 is hy...
|
|
WO2003032912A9 |
The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of tre...
|
|
WO/2004/087672A1 |
In one aspect, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of general formula (I), wherein R1-R6, Ra-RC, Q, Y1, Y2 and n are as defined herein, whereby the compos...
|
|
WO/2004/076395A1 |
The invention relates to a method for producing cyclopentanone and optionally caprolactone, by reacting a dicarboxylic acid solution in the presence of at least one catalyst. The invention also relates to the use of a dicarboxylic acid s...
|
|
WO/2004/062629A2 |
The invention provides novel apoptosis-inducing compounds that include isolated, purified isoapoptolidin, and selectively functionalized isoapoptolidin derivatives and stereoisomers thereof; selectively functionalized apoptolidin derivat...
|
|
WO/2004/058976A2 |
The present invention relates to the biosynthesis of polyketides and derives from the cloning of nucleic acids encoding a polyketide synthase and other associated proteins involved in the synthesis of the polyketide borrelidin. Materials...
|
|
WO/2004/052847A2 |
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula...
|
|
WO/2004/052837A2 |
Described are amino substituted hydroxyphenyl benzophenone derivatives of formula (I), wherein R1, and R2 independently from each other are; C1,-C20alkyl; C2-C20alkenyl; C3-C10,cycloalkyl; C3-C10cycloalkenyl; or R1, and R2 together with ...
|
|
WO/2004/041161A2 |
The present invention is directed to compounds of the formula (I) (wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R27, R28, R29, R30, R31, X, m, n and the dashed line are defined herein) which are useful as modulators of chemokine...
|
|
WO/2004/039773A2 |
Novel compounds and their use for modulationof L-Isoaspartyl (D-Aspartyl) 0-Metyltransferase and/or glyceraldehyde-3-phosphate dehydrogenase activity enable the prevention treatment or alleviation of diabetes, autoimmune diseases and neu...
|
